The two biologics Contract Development and Manufacturing Organizations (CDMOs), have announced their combination.
Backed by their common shareholder, Keensight Capital, the combination of Biovian and 3P extends the group’s value proposition to address complex customer needs across the entire development cycle, the companies state. Keensight Capital will continue to help the Group strengthen its position at a global level and ERES IV, advised by Elyan Partners, and Sodena, will each continue as minority shareholders alongside Keensight, maintaining their investment in the Group.
“We are thrilled about this opportunity and the new chapter for our combined companies. The consolidation of these two technically and financially strong players creates a powerful global end-to-end service provider. We are also extremely glad to be able to continue the journey alongside Keensight, jointly investing in the future development of the firm, and striving to further improve our client satisfaction as well as build a great workplace for our highly talented people,” says Antti Nieminen, CEO Biovian.
The combined Group, named 3PBIOVIAN, will offer end-to-end development and manufacturing services for all protein expression systems and viral vectors, both for Drug Substance and Drug Product, from preclinical to clinical development and commercial phases, the companies state. Through this combination, the Group will become one of the main independent European bio-CDMOs, with gross sales above EUR 75 million.
With over 500 professionals and operating across manufacturing facilities of 15,800 square meters, the group is now ideally positioned to effectively address the growing demands of the market, they state further. 3PBIOVIAN will leverage its manufacturing sites in Pamplona-Noáin (Spain) and Turku (Finland) as well as its commercial office in Boston, MA (United States) to address an extensive array of customer needs. Its end-to-end offering will span across multiple platforms (microbial and mammalian expression, adenoviruses, adeno-associated viruses, cell therapy and plasmids) and offers enhanced production scale flexibility via a diverse range of bioreactor sizes. 3PBIOVIAN will continue to be led by its team of professionals in the biologics industry.
Dámaso Molero Sánchez will serve as Group CEO
Dámaso Molero Sánchez (former 3P CEO) will serve as Group CEO supported by Deputy CEO Antti Nieminen (former Biovian CEO), Heidi Suuronen as CFO and Elena Erroba as CCO (Chief Commercial Officer).
“I am very delighted about this exciting new stage, which is nothing more than the consequence of the enormous and excellent work done by Biovian and 3P over the years. The combination of technology, capabilities and most importantly, the quality of the human team, positions us a leader in the highly dynamic international market for the development and manufacturing of advanced therapies. Together, we will be able to unleash the enormous potential for growth and value generation that we have accumulated over the years,” says Dámaso Molero Sánchez, CEO 3P Biopharmaceuticals.
The Board of Directors will includes several eminent industry veterans to assist the company in its journey through their strategic vision and expertise, the companies state, including Uwe Gottschalk, bringing more than 30 years of experience within the field of bioprocessing and protein purification technologies, Stefan Stoffel, bringing more than 30 years of experience in engineering, operational experience, and internationalization of CDMOs, and Tom Ransohoff, bringing more than 30 years of entrepreneurial and professional experience in the biopharma industry.
Featured photo of Antti Nieminen, Deputy CEO, and Dámaso Molero Sánchez, CEO, of 3PBIOVIAN